MX2022008547A - Virus de vacuna recombinante. - Google Patents

Virus de vacuna recombinante.

Info

Publication number
MX2022008547A
MX2022008547A MX2022008547A MX2022008547A MX2022008547A MX 2022008547 A MX2022008547 A MX 2022008547A MX 2022008547 A MX2022008547 A MX 2022008547A MX 2022008547 A MX2022008547 A MX 2022008547A MX 2022008547 A MX2022008547 A MX 2022008547A
Authority
MX
Mexico
Prior art keywords
vaccinia virus
recombinant vaccinia
rvv
competent
replication
Prior art date
Application number
MX2022008547A
Other languages
English (en)
Inventor
Michael Dale Eisenbraun
Joseph John Binder
David H Kirn
Douglas Hanahan
Clare Lees
Prajit Limsirichai
Avidal Liliana Maruri
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022008547A publication Critical patent/MX2022008547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona un virus de vacuna oncolítico recombinante competente para la replicación (RVV), composiciones que comprenden el RVV y el uso del RVV o composición para inducir la oncólisis en un individuo que tiene un tumor.
MX2022008547A 2020-01-09 2021-01-05 Virus de vacuna recombinante. MX2022008547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959083P 2020-01-09 2020-01-09
PCT/IB2021/050040 WO2021140435A1 (en) 2020-01-09 2021-01-05 Recombinant vaccinia virus

Publications (1)

Publication Number Publication Date
MX2022008547A true MX2022008547A (es) 2022-08-10

Family

ID=74175895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008547A MX2022008547A (es) 2020-01-09 2021-01-05 Virus de vacuna recombinante.

Country Status (11)

Country Link
US (1) US20230201283A1 (es)
EP (1) EP4087591A1 (es)
JP (1) JP2021118683A (es)
KR (1) KR20220125806A (es)
CN (1) CN115175690A (es)
AU (1) AU2021205287A1 (es)
BR (1) BR112022013521A2 (es)
CA (1) CA3167002A1 (es)
IL (1) IL294475A (es)
MX (1) MX2022008547A (es)
WO (1) WO2021140435A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7537390B2 (ja) 2021-07-19 2024-08-21 トヨタ自動車株式会社 蓄電装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
EP1648233A4 (en) 2003-07-08 2006-08-23 Univ Arizona VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
UA117294C2 (uk) * 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
ES2703341T3 (es) * 2013-03-14 2019-03-08 Genvivo Inc Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica
PE20160673A1 (es) * 2013-08-22 2016-07-21 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Terapias inmuno-oncoliticas
CN105765062B (zh) 2013-11-21 2020-12-11 国立大学法人鸟取大学 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
EP3973973A1 (en) * 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2019151836A1 (en) * 2018-02-05 2019-08-08 Sillajen, Inc. Oncolytic vaccinia virus expressing an immune checkpoint protein antagonist to treat cancer

Also Published As

Publication number Publication date
JP2021118683A (ja) 2021-08-12
US20230201283A1 (en) 2023-06-29
CN115175690A (zh) 2022-10-11
AU2021205287A1 (en) 2022-07-21
IL294475A (en) 2022-09-01
WO2021140435A1 (en) 2021-07-15
BR112022013521A2 (pt) 2022-09-13
KR20220125806A (ko) 2022-09-14
EP4087591A1 (en) 2022-11-16
CA3167002A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2020004578A (es) Composiciones de casz y metodos de uso.
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
Schweneker et al. The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence
EP4151737A8 (en) Methods for selectively modulating the activity of distinct subtypes of cells
SG11201810612TA (en) Novel genetically engineered vaccinia viruses
MX2024008058A (es) Adenovirus modificados.
NZ594355A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2017147553A3 (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CO6210761A2 (es) Vectores de virus oncoliticos de viruela
KR970701062A (ko) 폭스비루스(poxvirus) 성분의 조합에 기초한 파라뮤니티(paramunity) 유발인자(inducer), 그의 제조방법 및 그의 약제에의 이용
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
CO2023009114A2 (es) Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
MX2022008547A (es) Virus de vacuna recombinante.
WO2020014591A8 (en) Apmv and uses thereof for the treatment of cancer
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
CA3138834A1 (en) Oncolytic adenovirus and checkpoint inhibitor combination therapy
MX2021003539A (es) Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella.
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BR112022006926A2 (pt) Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2)
AR120690A1 (es) Daao modificada y uso de la misma
MX2021010458A (es) Uso de virus oncoliticos para el tratamiento del cancer.
MX2022007237A (es) Variante del virus de la vacuna oncolitica y metodos de uso del mismo.
AR117877A1 (es) Rhabdovirus recombinante que codifica ccl21
WO2022013696A3 (en) Recombinant vaccinia virus